Products

VITEK MS
bioMérieux
Lab & Diagnostics
VITEK MS by bioMérieux is an automated mass spectrometry system utilizing Matrix Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) technology for the rapid identification of microorganisms from clinical cultures. What it does: VITEK MS identifies bacteria and fungi, including mycobacteria, Nocardia, and molds, by analyzing their protein makeup to create a unique spectral fingerprint. This spectrum […]

See all 1 product →

About BIOMERIEUX

bioMérieux is a French multinational biotechnology company and a world leader in in vitro diagnostics. The company provides diagnostic solutions, including reagents, instruments, software, and services, to determine the source of diseases and contamination, ultimately aiming to improve patient health and ensure consumer safety. Their products are utilized in various critical areas such as diagnosing infectious diseases, cancer screening, monitoring cardiovascular emergencies, and detecting microorganisms in agri-food, pharmaceutical, and cosmetic products.

For physicians, bioMérieux’s offerings are crucial in guiding clinical decisions, as 60-70% of medical decisions rely on diagnostic test results. The company is particularly focused on infectious disease management, striving to reduce the time to results for faster and more automated diagnostics. They also develop high medical value prognostic and predictive tests in oncology and cardiovascular diseases, many of which run on their widely installed VIDAS platforms. bioMérieux invests significantly in research and development, dedicating 12-13% of its sales to R&D, which is among the highest in the in vitro diagnostics industry.

In the realm of healthcare AI, bioMérieux is actively leveraging artificial intelligence and machine learning to enhance diagnostic accuracy and efficiency, particularly in the detection of antibiotic resistance and early prediction of sepsis-related shock. They have partnered with institutions like Mila – Quebec Artificial Intelligence Institute to develop AI models for genomic analysis, which could improve the prediction of antibiotic resistance. This focus on AI aims to transform critical care by providing earlier warning signs and enabling more personalized treatment strategies.

Focus Areas

In vitro diagnostics Infectious Diseases Clinical Microbiology Industrial Microbiological Control Molecular Biology Immunoassays Antimicrobial Resistance (AMR) Sepsis Food Safety Pharmaceutical Quality Control Genomic Analysis Artificial Intelligence in Diagnostics

Business Intelligence

TechnologyCloud-native (e.g., EPISEQ SARS-COV-2, BIOMÉRIEUX VISION SUITE), Molecular Biology (BIOFIRE® FilmArray®, BIOFIRE® SPOTFIRE® System, Extreme PCR technology), Mass Spectrometry (VITEK® MS PRIME), Automated Identification and Antimicrobial Susceptibility Testing (VITEK® COMPACT PRO, VITEK® 2 Advanced Expert System™), Machine Learning for genomic analysis and diagnostic insights, Digital and AI tools merging bioinformatics and genomics.

What Physicians Need to Know

In Vitro Diagnostics
BIOMERIEUX is a global leader in in vitro diagnostics, offering innovative solutions for diagnosing infectious diseases and other conditions. They provide a wide range of increasingly sophisticated diagnostic tests to establish or confirm a diagnosis, determine appropriate treatment, and monitor its efficacy. Their solutions aim to deliver rapid, high-impact, and actionable results.
Infectious Diseases
BIOMERIEUX has a long history and extensive expertise in the fight against infectious diseases, providing tests for early detection and monitoring. They focus on major public health challenges, including gastrointestinal, respiratory, sexually transmitted, and urinary tract infections, as well as tuberculosis.
Clinical Microbiology
They offer microbiology diagnostic solutions that provide critical information from risk assessment and early diagnosis to treatment and patient follow-up. This includes rapid identification (ID) and antimicrobial susceptibility testing (AST) directly from positive blood cultures.
Industrial Microbiological Control
BIOMERIEUX provides solutions for industrial microbiological control, particularly in food safety and pharmaceutical quality control.
Molecular Biology
Their molecular biology offerings contribute to rapid and accurate pathogen identification. This includes syndromic testing, which offers a comprehensive approach to diagnosis for various infections.
Immunoassays
BIOMERIEUX's immunoassay testing allows for a variety of diagnostic tests, including immunochemistry, infectious disease, and emergency and critical care panel tests. Their VIDAS® systems offer on-demand immunoassay testing with a broad menu of high-quality assays.
Antimicrobial Resistance (AMR)
A significant focus for BIOMERIEUX is combating antimicrobial resistance (AMR), a top global public health threat. They provide rapid diagnostic tests and data-driven solutions to support targeted treatment and antimicrobial stewardship programs.
Sepsis
BIOMERIEUX offers solutions for the early detection and assessment of sepsis risk, which is crucial for improved patient outcomes. Their diagnostics help clinicians quickly distinguish sepsis from other conditions and initiate appropriate antimicrobial therapy.
Food Safety
They leverage microbiology expertise and cutting-edge science to help achieve food safety and quality objectives. Their 'Augmented Diagnostics' approach combines traditional solutions with digital and AI tools, bioinformatics, and genomics to provide deeper insights into microbial contamination.
Pharmaceutical Quality Control
BIOMERIEUX provides digital solutions like 3P® CONNECT for securing sample traceability, reducing errors, and supervising environmental monitoring data in real-time for greater process efficiency in pharmaceutical quality control.
Genomic Analysis
They are developing AI models applied to genomic analysis to improve the prediction of antibiotic resistance and enhance the value of genomic information for infectious disease diagnosis.
Artificial Intelligence in Diagnostics
BIOMERIEUX integrates AI and machine learning into infectious disease diagnostics to enhance accuracy of pathogen identification, improve interpretation of images, and support real-time outbreak detection. They are also using AI to predict sepsis-related shock earlier, turning routine hospital data into early warning signs.
Physician Tip

For physicians, BIOMERIEUX stands out due to its commitment to providing rapid, accurate, and actionable diagnostic insights that directly impact patient care. Their solutions are designed to streamline workflows, support timely clinical decision-making, and guide appropriate treatment, especially in critical areas like sepsis and antimicrobial resistance. The company emphasizes the medical value of diagnostics in improving patient outcomes, reducing unnecessary antibiotic exposure, and optimizing hospital stays. Their focus on 'Augmented Diagnostics' and AI integration aims to provide earlier predictions and more personalized care.

BIOMERIEUX utilizes a diverse technology stack and offers connectivity and data IT solutions. Their CLARION cloud-based software-as-a-service (SaaS) offering, powered by SAS Viya, accelerates access to information about antimicrobial resistance for clinicians. They also provide digital solutions like 3P® CONNECT for data supervision and VILINK® for remote instrument monitoring, ensuring continuous testing operations and efficient data management.

Products by BIOMERIEUX

1 product in the directory

VITEK MS
bioMérieux
Lab & Diagnostics
VITEK MS by bioMérieux is an automated mass spectrometry system utilizing Matrix Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) technology for the rapid identification of microorganisms from clinical cultures. What it does: VITEK MS identifies bacteria and fungi, including mycobacteria, Nocardia, and molds, by analyzing their protein makeup to create a unique spectral fingerprint. This spectrum […]

What the Web Says

BIOMERIEUX generally receives mixed to positive reviews as an employer, with many highlighting strong benefits, job security, and a mission-driven culture. However, some employees express concerns about inconsistent management, slow corporate bureaucracy, and compensation not always aligning with the cost of living. Product reviews are less prevalent in the search results, but some users on Reddit describe their interfaces as challenging to use.

Overall: Mixed

Strengths

  • Excellent job security and fair pay.
  • Comprehensive benefits package, including health benefits and 401(k) match.
  • Collaborative and supportive team environments with smart coworkers.
  • Mission-driven work focused on public health and patient impact.
  • Good opportunities for career growth and development.
  • Positive company culture in many locations, described as laid-back and family-oriented.

Limitations

  • Slow corporate bureaucracy and a highly regulated industry.
  • Inconsistent management, with issues like micromanagement and favoritism.
  • Promotions sometimes tied to relationships rather than merit.
  • Compensation may be below local averages for skill level and job, especially compared to competitors.
  • Challenging or unintuitive product interfaces.
  • Some employees feel undervalued or that management lacks concern for their well-being.

Based on reviews from: Indeed.com, Comparably, Built In, Reddit, Handshake

Last updated: 2026-10-19

Videos

News, demos, and interviews about BIOMERIEUX.

Loading videos...

Videos load interactively. If none appear, search YouTube for BIOMERIEUX →

View all on YouTube

Press & Coverage

bioMérieux Press Release
WHO Grants Emergency Use Listing for BIOFIRE® Global Fever Special Pathogens Panel, Expanding Access to Differential Diagnostics for the Ebola Response
The WHO has granted Emergency Use Listing for bioMérieux's BIOFIRE® Global Fever Special Pathogens Panel, aiming to improve access to differential diagnostics for the Ebola response. This expands diagnostic capabilities for critical infectious diseases.
2026-10
MarketScreener
bioMérieux Launches SPINCHIP, Featuring Its First Test For The Measurement Of High-Sensitivity Cardiac Troponin I From A Single Drop Of Blood
bioMérieux has launched SPINCHIP, a new testing solution for cardiac emergencies that measures high-sensitivity cardiac Troponin I from a single drop of blood. This innovation aims to provide rapid results for critical cardiac diagnostics.
2026-09
bioMérieux Company News
Surviving Sepsis: How Diagnostics Can Help Improve Outcomes When Every Hour Matters
This article discusses how faster diagnostic information can help healthcare teams identify the cause of infection sooner in sepsis patients, supporting earlier and better-informed care decisions.
2026-09
bioMérieux Company News
bioMérieux Launches PCR Testing Solution to Verify Probiotic Species in Dietary Supplements Manufacturing
bioMérieux introduces GENE-UP® PROBIOTIC SPECIES ID, a first-of-its-kind commercialized species-level identification PCR solution for verifying probiotic species in dietary supplement manufacturing.
2026-07
bioMérieux Press Release
WATCHFIRE™ Solution now available for wastewater monitoring in the United States through BioFire Defense
bioMérieux announced that its WATCHFIRE™ Solution multiplex PCR test for wastewater monitoring is now available through BioFire Defense, screening for over 40 pathogens causing respiratory and gastrointestinal illnesses.
2026-07
bioMérieux Company News
bioMérieux Invests in Plair to Advance Real-Time Environmental Monitoring for Pharmaceutical Industry
bioMérieux has invested over one million Swiss Francs in Plair, a company offering a breakthrough solution for real-time microbial detection and air sampling, to advance environmental monitoring in the pharmaceutical industry.
2026-03
PR Newswire
bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing
bioMérieux launched BIOFIRE® SPOTFIRE® for pharmaceutical industries, an innovative molecular testing system designed to transform quality control and redefine rapid mycoplasma testing.
2026-04
MedTech Innovator
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
bioMérieux is acquiring Day Zero Diagnostics' assets, including NGS workflows and bioinformatics, to enhance its next-generation sequencing and rapid diagnostics capabilities for combating antibiotic-resistant infections.
2025-06

Frequently Asked Questions

BIOMERIEUX is a world leader in clinical microbiology and offers a comprehensive range of in vitro diagnostic solutions for infectious diseases. Their portfolio includes instruments, reagents, and software for microbiology, immunoassays, and molecular biology, designed to provide rapid, high-impact, and actionable results.
BIOMERIEUX is deeply committed to combating AMR, offering diagnostic solutions that aid in detecting, identifying, and treating drug-resistant pathogens to optimize antimicrobial therapy. For sepsis, they provide comprehensive diagnostic solutions aimed at faster, actionable decision-making to improve patient care and outcomes.
BIOMERIEUX is actively integrating Artificial Intelligence (AI) into its diagnostic technologies through strategic partnerships, such as with Mila - Quebec Artificial Intelligence Institute. This collaboration aims to enhance the accuracy and efficiency of in vitro diagnostic tools, improve antibiotic resistance prediction through genomic analysis, and support real-time outbreak detection.
BIOMERIEUX offers a comprehensive portfolio of solutions for industrial microbiological control, helping the food and pharmaceutical industries ensure product quality and safety. This includes efficient solutions for microbial quality control in pharmaceutical products, and advanced diagnostics, data analytics, and genomics for food safety and quality.
BIOMERIEUX provides robust customer support with over 300 professionals in the US, offering 24/7 technical assistance and on-site field service engineers. They also forge global partnerships with biotech firms, researchers, and physicians to drive advances in diagnostics and remain at the cutting edge of medical and scientific developments.

Related Companies

AIRA Matrix is a healthcare AI company that develops cutting-edge artificial intelligence solutions for life sciences applications, with a strong emphasis on deep learning for medical image analysis. Their innovative products and services are designed to enhance diagnostic accuracy, improve workflow efficiency, and reduce turnaround times in pathology laboratories. The company provides diagnostic, prognostic, and […]

AI-LabTest is a secure, AI-powered digital health platform designed to help individuals understand their medical lab reports. The platform analyzes uploaded bloodwork or diagnostic results (in PDF, JPG, or TXT formats) and translates complex medical data into clear, personalized summaries. These summaries highlight key findings, potential implications, and practical next steps in patient-friendly language. The […]

Google DeepMind is a British-American artificial intelligence (AI) research laboratory and a subsidiary of Alphabet Inc.. Formed in April 2023 through the merger of DeepMind and Google AI’s Google Brain division, the company focuses on advancing artificial general intelligence (AGI) and developing AI systems for widespread public benefit and scientific discovery. Their work involves an […]

Tempus AI, Inc. is an American health technology company that utilizes data and artificial intelligence to deliver precision medicine services. The company was founded with the mission to bring data-driven precision medicine into routine care, initially focusing on oncology. Tempus has developed a platform that sequences tumor samples and employs AI models to assist physicians […]

LabLynx is a privately held American laboratory informatics company that specializes in developing, supporting, and marketing Laboratory Information Management System (LIMS) solutions. The company has a long history in the industry, having introduced one of the first browser-based LIMS products in 1997. LabLynx’s primary offerings include ELab LIMS, a configurable cloud-based LIMS that serves various […]

August AI is a healthcare artificial intelligence company that has developed an AI-powered digital health companion. This platform is designed to provide accessible medical care and health guidance, acting as a ‘health companion’ rather than a replacement for clinical visits. It assists users in understanding symptoms, interpreting medical reports, and managing ongoing treatment. The company’s […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.